orantinib

Small moleculeexperimental

Clinical trial activity

4 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
2
Phase 3
1
Phase 4
0

Earliest trial started Jul 1, 2001 (NCT00024206)

Timeline

2000s

  1. Jan 1, 2001

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Mol. weight
310.35 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 5-((1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-2,4-dimethyl-1h-pyrrole-3-propanoic acid
  • orantinib
  • orantinib
  • orantinib
  • orantinib
  • orantinib
  • su006668
  • su6668
  • su 6668
  • su-6668
  • su-6668
  • tsu 68
  • tsu-68
  • tsu-68
  • tsu-68
  • (z)-3-(2,4-dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1h-pyrrol-3-yl)-propionic acid
  • (z)-3-(2,4-dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1h-pyrrol-3-yl)propionic acid

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01465464Phase 3Dec 1, 2010Otsuka
NCT00784290Phase 1/Phase 2 (Phase 2)Sep 1, 2003Otsuka, Yamanashi Prefectural Central Hospital
NCT00024063Phase 1Sep 13, 2001National Cancer Institute (NCI), University of California, Los Angeles
NCT00024206Phase 1Jul 1, 2001National Cancer Institute (NCI), University of Texas at Houston
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government2112001
OtsukaFor profit2222003
University of California, Los AngelesAcademic/Hospital1112001
University of Texas at HoustonAcademic/Hospital1012001
Yamanashi Prefectural Central HospitalAcademic/Hospital1012003
5 organizations
Page 1 / 1